6212 related articles for article (PubMed ID: 15669880)
1. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
4. Comparative tolerability profiles of oral antidiabetic agents.
Krentz AJ; Ferner RE; Bailey CJ
Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
[TBL] [Abstract][Full Text] [Related]
5. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
6. Recent developments and emerging therapies for type 2 diabetes mellitus.
Evans AJ; Krentz AJ
Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
8. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
[TBL] [Abstract][Full Text] [Related]
9. Effects of current therapeutic interventions on insulin resistance.
Kobayashi M
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S32-40. PubMed ID: 11220286
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic drugs: an overview.
Melander A
Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
[TBL] [Abstract][Full Text] [Related]
11. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of diabetes in metabolic syndrome].
Pelikánova T
Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
[TBL] [Abstract][Full Text] [Related]
13. Antihyperglycaemic agents. Drug interactions of clinical importance.
Scheen AJ; Lefèbvre PJ
Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
[TBL] [Abstract][Full Text] [Related]
14. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Hermansen K; Mortensen LS
Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
[TBL] [Abstract][Full Text] [Related]
15. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Wolffenbuttel BH; van Haeften TW
Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
[TBL] [Abstract][Full Text] [Related]
16. Oral antidiabetic agents. A guide to selection.
Scheen AJ; Lefèbvre PJ
Drugs; 1998 Feb; 55(2):225-36. PubMed ID: 9506242
[TBL] [Abstract][Full Text] [Related]
17. The use of sulphonylureas in the elderly.
Graal MB; Wolffenbuttel BH
Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
[TBL] [Abstract][Full Text] [Related]
18. Management of antidiabetic medications in overdose.
Spiller HA
Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
[TBL] [Abstract][Full Text] [Related]
19. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
[TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.
Evans A; Krentz AJ
Drug Saf; 1999 Jul; 21(1):7-22. PubMed ID: 10433350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
